The best indicator for Moderna (MRNA)
We backtested 366 indicators across daily, weekly and hourly charts on real Moderna (MRNA) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
Stoch RSI (fast)
On the daily chart, this is the strongest risk-adjusted edge we found for Moderna (MRNA) over ~7.5 years — beating buy-and-hold by 38.8% CAGR.
Best multi-indicator combo
Going long only when all 2 agree was the strongest confluence setup we found for Moderna (MRNA) — beating buy-and-hold by 34.2% CAGR, out-of-sample. Fewer, higher-conviction trades than any single indicator.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | Stoch RSI (fast) ✓ | Daily | 52.2% | 1.06 | -62.9% | 42.9% | 191 | 38.8% |
| 2 | Chande Forecast Osc. ✓ | Daily | 45.4% | 0.98 | -59.8% | 49.3% | 201 | 32.0% |
| 3 | Ulcer Index ✓ | Daily | 37.8% | 0.98 | -33.7% | 44.4% | 45 | 24.4% |
| 4 | Ehlers SuperSmoother ✓ | Daily | 46.2% | 0.97 | -65.2% | 44.1% | 236 | 32.8% |
| 5 | Impulse MACD ✓ | Daily | 38.0% | 0.97 | -37.1% | 52.7% | 74 | 24.6% |
| 6 | HMA 9/21 Cross ✓ | Daily | 45.0% | 0.97 | -55.5% | 48.4% | 128 | 31.6% |
| 7 | VuManChu Cipher B ✓ | Daily | 33.0% | 0.94 | -60.7% | 55.3% | 76 | 19.6% |
| 8 | EMA 10/40 Cross ✓ | Daily | 41.9% | 0.92 | -48.3% | 42.9% | 21 | 28.5% |
| 9 | SMC: Break of Structure ✓ | Daily | 42.5% | 0.91 | -61.5% | 50.0% | 18 | 29.2% |
| 10 | Fisher Transform | Daily | 41.0% | 0.9 | -81.1% | 43.4% | 175 | 27.6% |
| 11 | KDJ ✓ | Daily | 39.8% | 0.9 | -66.9% | 43.3% | 171 | 26.5% |
| 12 | VIDYA 30 Trend ✓ | Daily | 41.3% | 0.9 | -64.3% | 46.9% | 32 | 28.0% |
| 13 | ALMA 200 Trend ✓ | Daily | 39.3% | 0.9 | -55.1% | 45.0% | 20 | 25.9% |
| 14 | Ichimoku Cloud ✓ | Daily | 38.0% | 0.89 | -47.8% | 44.0% | 25 | 24.7% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For Moderna (MRNA), Stoch RSI (fast) on the daily timeframe gave the best balance of return and risk in our test. It beat buy-and-hold — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.